NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $7.19 +0.39 (+5.74%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends About KALA BIO Stock (NASDAQ:KALA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KALA BIO alerts:Sign Up Key Stats Today's Range$6.66▼$7.2450-Day Range$5.11▼$7.1952-Week Range$4.21▼$10.97Volume36,738 shsAverage Volume87,204 shsMarket Capitalization$20.25 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingBuy Company OverviewKALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade KALA BIO Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks85th Percentile Overall ScoreKALA MarketRank™: KALA BIO scored higher than 85% of companies evaluated by MarketBeat, and ranked 223rd out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKALA BIO has only been the subject of 1 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KALA BIO are expected to grow in the coming year, from ($11.76) to ($6.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.80% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KALA BIO has recently decreased by 2.01%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.35 Percentage of Shares Shorted0.80% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KALA BIO has recently decreased by 2.01%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News SentimentN/A News SentimentKALA BIO has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for KALA BIO this week, compared to 2 articles on an average week.Search Interest2 people have searched for KALA on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have not sold or bought any company stock.Percentage Held by Insiders13.40% of the stock of KALA BIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address KALA Stock News HeadlinesTravis Kelce's Ex Stirs Up Drama With Another TaylorOctober 15, 2024 | msn.comTaylor Swift Fans Rush to Support Caitlin Clark After Angel Reese Interviews Travis Kelce's ExOctober 13, 2024 | msn.comElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 29, 2024 | Porter & Company (Ad)This new biography about architect Charles Correa explores his visionary geniusOctober 12, 2024 | msn.comAthlos, new women’s track venture, plans future event after drawing 3 million viewersOctober 11, 2024 | nytimes.comObama, the ‘hopey-changey guy,’ tries to close the deal for HarrisOctober 11, 2024 | msn.comNorth West Puts Mom Kim Kardashian on Blast for Not Cooking for Their FamilyOctober 11, 2024 | newsweek.comBiohacking: This Couple Plans To Live Until 150 Years Using This Increasingly Popular Wellness Trend. Find Out MoreOctober 6, 2024 | msn.comSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $7.00 at the beginning of the year. Since then, KALA shares have increased by 2.7% and is now trading at $7.19. View the best growth stocks for 2024 here. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) released its earnings results on Tuesday, August, 6th. The company reported ($3.16) earnings per share for the quarter, topping the consensus estimate of ($4.40) by $1.24. When did KALA BIO's stock split? Shares of KALA BIO reverse split before market open on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings8/06/2024Today10/29/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALA CUSIPN/A CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$18.00 Low Stock Price Target$15.00 Potential Upside/Downside+129.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($15.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-396.03% Return on Assets-66.84% Debt Debt-to-Equity Ratio1.97 Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual Sales$3.89 million Price / Sales5.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book2.58Miscellaneous Outstanding Shares2,816,000Free Float4,225,000Market Cap$20.25 million OptionableNot Optionable Beta-2.12 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:KALA) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.